This clinical trial focuses on treating patients with high grade brain tumors using a combination of two medications. The study will test Tarlatamab (also known as AMG 757), which is given through an intravenous infusion, together with Temozolomide, which is taken by mouth. These medications will be used to treat different types of brain tumors, including those with specific genetic changes.
The purpose of this study is to determine if this combination of medications is safe to use and to evaluate how well it works in treating brain tumors. The study is divided into two parts. The first part will check the safety of combining these medications, while the second part will look at how effective this treatment is in different groups of patients with various types of brain tumors.
During the study, patients will receive both medications according to a specific schedule. Tarlatamab will be given as an infusion into a vein, while Temozolomide will be taken as regular oral doses. The treatment will continue while patients are benefiting from it and not experiencing unacceptable side effects. Doctors will monitor patients’ responses to the treatment using brain scans and regular health checks throughout the study period.
France 
